Diagnostic Evaluation and Criteria for Thrombocytosis

Definition and Classification

• Sustained platelet count ≥ 450 × 10⁹/L on multiple measurements defines thrombocytosis and is the first step in confirming the diagnosis. 1

Primary Thrombocytosis (Essential Thrombocythemia) Diagnostic Criteria

• Essential thrombocythemia (ET) is diagnosed when a patient has:
• A platelet count > 600 × 10⁹/L without an identifiable secondary cause should raise suspicion for primary thrombocytosis. 1
• Persistent thrombocytosis after resolution of a potential secondary trigger also supports a primary etiology. 1
• Patients lacking the JAK2V617F mutation can still be diagnosed with ET if the first three criteria are met, even when a concurrent reactive condition is present. 1

Secondary Thrombocytosis – Common Causes

All prevalence figures are derived from the same source. 1

Diagnostic Algorithm – Key Evaluation Steps

• Step 1 – Confirmation: Verify platelet count ≥ 450 × 10⁹/L on at least two separate occasions. 1
• Step 2 – Exclude Reactive Triggers:
• Step 3 – Iron‑Deficiency Evaluation: In patients with iron deficiency, perform a therapeutic iron trial to rule out concealed polycythemia vera before labeling the thrombocytosis as secondary. 1

Bone Marrow Evaluation

• Bone‑marrow biopsy is mandatory in patients > 60 years (or any age with systemic symptoms) to:

Molecular and Cytogenetic Testing

• JAK2V617F testing is the first‑line molecular assay for clonal confirmation. 1
• If JAK2V617F is negative, additional testing for CALR and MPL mutations should be considered (though not explicitly cited).
• Cytogenetics: Demonstrate the absence of the Philadelphia chromosome/BCR‑ABL fusion to exclude chronic myeloid leukemia. 1

Common Diagnostic Pitfalls (and How to Avoid Them)

• Failing to perform a bone‑marrow biopsy in patients > 60 years with persistent thrombocytosis can miss early myelofibrosis or myelodysplasia. 1
• Not conducting a therapeutic iron trial in iron‑deficient individuals may lead to misclassification of concealed polycythemia vera as secondary thrombocytosis. 1
• Assuming that a concurrent reactive condition automatically excludes essential thrombocythemia; ET can coexist with reactive causes if the core diagnostic criteria are satisfied. 1

Diagnostic Criteria and Evaluation of Thrombocytosis

Primary Thrombocytosis

• The World Health Organization recommends that diagnosis of Essential Thrombocythemia (ET) requires meeting all four criteria, including sustained platelet count ≥450×10⁹/L, bone marrow biopsy showing megakaryocytic proliferation, exclusion of other myeloid neoplasms, and demonstration of JAK2V617F or other clonal marker 2, 3
• The American Society of Hematology suggests that JAK2V617F mutation is present in 86% of primary thrombocytosis cases, and its detection is essential for diagnosis 2
• Polycythemia vera is characterized by the presence of JAK2V617F mutation in >90% of cases, with elevated hemoglobin/hematocrit as the primary feature 2
• Primary myelofibrosis is associated with JAK2V617F mutation in nearly 50% of cases, with characteristic bone marrow fibrosis and atypical megakaryocytes 2

Secondary Thrombocytosis

• The European Hematology Association notes that tissue injury, infection, and chronic inflammatory disorders are common causes of secondary thrombocytosis, accounting for 32.2%, 17.1%, and 11.7% of cases, respectively 3, 2
• Iron deficiency anemia can cause thrombocytosis, even without anemia, and iron studies should be performed to detect iron deficiency 3, 2
• Inflammatory markers, such as ESR and CRP, should be used to identify chronic inflammation 4

Diagnostic Algorithm

• The National Comprehensive Cancer Network recommends that initial evaluation of thrombocytosis should include complete blood count with differential, peripheral blood smear examination, and exclusion of pseudothrombocytosis 5, 6
• Bone marrow examination is mandatory in patients >60 years or with systemic symptoms to exclude myelodysplastic syndromes, leukemias, or other malignancies 5, 6
• Molecular testing, including JAK2V617F mutation testing, should be performed when primary thrombocytosis is suspected 2

Clinical Significance and Thrombotic Risk

• The International Society on Thrombosis and Haemostasis states that primary thrombocytosis carries a significantly higher thrombotic risk than secondary thrombocytosis 3, 2
• The presence of a reactive condition does not exclude ET if WHO criteria are otherwise met 3, 2

Thrombocytosis Diagnosis and Management

Diagnostic Criteria and Risk Stratification

• The European Heart Journal recommends evaluating mean corpuscular volume (MCV) to assess iron deficiency, which can cause thrombocytosis even without anemia, with microcytosis (MCV <80 fL) indicating iron deficiency requiring supplementation 7
• The American Journal of Hematology suggests that CALR and MPL mutation testing should be performed if JAK2 negative, and that age >60 years, prior thrombosis, JAK2V617F mutation presence, cardiovascular risk factors, and leukocytosis >11×10⁹/L are risk factors for thrombosis in primary thrombocytosis 8
• The American Journal of Hematology also notes that leukocytosis confers a 60% increase in thrombotic risk in essential thrombocythemia, and that extreme thrombocytosis >1,000,000/μL actually confers lower thrombotic risk but higher bleeding risk 8